<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cefozopran (CZOP) was used as an initial antibacterial therapy for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>CZOP was given at a daily dose of 4 g by drip intravenously to patients who were febrile over 38 degrees C and were suspected as having <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>As underlying diseases, 8 patients had <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 9 <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 2 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA), 2 adult T cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ATLL</z:e>), 28 non Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), and 2 <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0001794'>Bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> diagnosed were <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 7 patients, suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 32, <z:e sem="disease" ids="C0006277" disease_type="Disease or Syndrome" abbrv="">bronchitis</z:e> in 6, <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in 5 and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002586'>peritonitis</z:hpo> in 1 </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical responses among 51 evaluable cases were excellent in 14, good in 15, fair in 3, poor in 19 and the overall response rate was 57% </plain></SENT>
<SENT sid="5" pm="."><plain>The overall response rates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, ALL, AA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ATLL</z:e>, NHL and MM were 56%, 63%, 100%, 50%, 50%, and 100%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Those for <z:hpo ids='HP_0100806'>sepsis</z:hpo>, suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo>, <z:e sem="disease" ids="C0006277" disease_type="Disease or Syndrome" abbrv="">bronchitis</z:e>, <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002586'>peritonitis</z:hpo> were 14%, 63%, 100%, 40%, and 0%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>This therapy was effective in 53% (9/17) of patients whose granulocyte count remained below 500/microliter throughout the course of CZOP therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Six <z:mp ids='MP_0001794'>bacterial</z:mp> and one fungal strains were isolated from blood and sputum of six patients including five <z:hpo ids='HP_0100806'>sepsis</z:hpo> cases; two bacteria were eradicated and <z:mp ids='MP_0001794'>bacterial</z:mp> change was observed in one case </plain></SENT>
<SENT sid="9" pm="."><plain>As side adverse effects, 10 patients had <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo>, 1 <z:hpo ids='HP_0001903'>anemia</z:hpo>, 2 proteinemia, 1 indirect <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">bilirubinemia</z:e>, 2 <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and 1 <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>We tried to establish a scoring system for the severities of patients with their <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, underlying diseases, treatments for the underlying disease, and granulocyte counts in order to evaluate the efficacy of CZOP more precisely </plain></SENT>
<SENT sid="11" pm="."><plain>This scoring system was consisted of three grades; severe, moderate, and mild </plain></SENT>
<SENT sid="12" pm="."><plain>CZOP was effective on mild and moderate grades </plain></SENT>
<SENT sid="13" pm="."><plain>These results indicate that the initial antibacterial therapy by CZOP is useful for the treatment of mild and moderate grade <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
</text></document>